Eli Lilly Stock: Why the Weight-Loss Boom Is Just Beginning @goingpublicwithrossmandell
Eli Lilly Stock: Why the Weight-Loss Boom Is Just Beginning  @goingpublicwithrossmandell
Uploaded October 2026 | Updated November 2026, 5 days ago
Join Ross’s Patreon Community for exclusive content and LIVE events
patreon.com/cw/TheRealRossMandell?utm_campaign=creatorshare_creator

Is Eli Lilly stock still in the early stages of the weight-loss boom? In this episode of Going Public with Ross Mandell, Ross breaks down his bullish outlook on LLY stock and explains why Mounjaro and Zepbound could be just the beginning. Explore how diabetes treatments, obesity drugs, and the growing GLP-1 market fit into his investment thesis.

The discussion covers oral weight-loss treatments such as orforglipron, retatrutide’s clinical development, and Lilly’s plans to expand manufacturing and reach more patients worldwide. Ross examines the company’s earnings, revenue growth, and drug pipeline, explaining why he sees an opportunity extending beyond today’s blockbuster injections.

Ross also addresses Eli Lilly’s stock pullback, valuation, competition from Novo Nordisk and other drugmakers, and the execution risks investors should watch. Learn which developments he’s tracking—from clinical trial results and international expansion to production capacity and financial guidance—and why a strong business still needs to justify its stock price. Subscribe to Going Public for more stock market analysis, healthcare stocks, and emerging investment themes.

About Ross Mandell:
Ross Mandell is a former Wall Street professional, entrepreneur, author, and capital formation expert. On Going Public with Ross Mandell, Ross interviews athletes, entrepreneurs, investors, doctors, creators, and high performers about success, failure, reinvention, money, health, business, and what it takes to rebuild after adversity.

This content is for informational and educational purposes only and does not constitute financial or investment advice.

🔗 Links & Resources
📌 Book A Call With Ross
buy.stripe.com/9B64gydlh4dJfhXecP5Vu08

📲 Follow Ross Mandell on Instagram
instagram.com/rossmandell

⏱️ Chapters
00:00 Eli Lilly Stock: The Next Phase of the Weight-Loss Boom
01:13 Eli Lilly’s History: From Insulin to Obesity Drugs
02:16 Mounjaro and Zepbound: Eli Lilly’s Revenue Growth
03:21 Orforglipron: The Oral Weight-Loss Pill Opportunity
05:20 Eli Lilly’s Manufacturing Expansion
06:12 Retatrutide Clinical Trials: The Triple-Action Obesity Drug
07:43 GLP-1 Research: New Data and Combination Treatments
08:22 Eli Lilly’s Drug Pipeline Beyond Weight Loss
09:07 LLY Stock Pullback and Revenue Guidance
10:16 Eli Lilly Stock Valuation and Novo Nordisk Competition
11:30 Why Ross Mandell Is Bullish on Eli Lilly Stock
13:18 Eli Lilly Stock: Key Catalysts and Risks to Watch
14:07 Why the Weight-Loss Boom Could Be Just Beginning
Eli Lilly Stock: Why the Weight-Loss Boom Is Just BeginningContent Creation Is Todays Manifest DestinyGossip Destroys CharacterMeta Finds A Way To MultiplyThey Laughed When I Said Id Be In The History BooksHIGHEST EARNING Law Firm In The World And They Worked On MY CASESurrender_ The Business Guys Secret Weapon Revealed!I Predicted NVIDIA TWO YEARS AGOStock Market Crash Warning: What History Says Happens NextRisk mitigation. What separates investors from gamblers.Quality Rocks🔥🔥🔥 #finance #stocks #podcast #stockmarket #crypto #iran  #iranwar #btc #ethereumIONQ Has been Aggressively Acquiring Companies. Thats a BIG SIGN of whats coming
Ross Mandell |

Eli Lilly Stock: Why the Weight-Loss Boom Is Just Beginning

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER